Use of a skin explant model for predicting GVHD in HLA-matched bone marrow transplants: Effect of GVHD prophylaxis

Bone Marrow Transplantation

Volumn 24, Issue 8, 1999, Pages 857-863

  Dickinson, A M ^a   Hromadnikova I ^b   Sviland, L ^c   Jackson, G H ^a   Taylor, P R A ^a   Vavrinec J ^b   Sedlacek P ^b   Cermakova M ^b   Stary J ^a   Vitek A ^a   Sajdova J ^d   Proctor, S J ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Predicting graft versus host disease; Skin explant model

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA ANTIGEN; MELPHALAN; METHOTREXATE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; EXPLANT; GRAFT VERSUS HOST REACTION; HLA MATCHING; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PREDICTION; PRIORITY JOURNAL; SKIN;

EID: 0345465914     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702002     Document Type: Article

References (27)

1. Bortin MM, Horowitz MM, Mrsic M et al. Progress in bone marrow transplantation for leukemia: a preliminary report from the Advisory Committee of the International Bone Marrow Transplant Registry. Trans Proc 1991; 23: 61-62.
2. Storb R, Buckner CD. Human bone marrow transplantation. Eur J Clin Invest 1990; 20: 119-132.
3. Ringdén O, Deeg HJ. Clinical spectrum of graft-versus-host disease. In: Ferrara JLM, Deeg HJ, Burakoff SJ (eds). Graft-Versus-Host Disease. Marcel Dekker: New York, 1997, pp 525-559.
4. Dickinson AM, Sviland L, Jackson G et al. Cytokine involvement in predicting clinical graft-versus-host disease (GVHD) in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1994; 13: 65-70.
5. Dickinson AM, Sviland L, Carey PJ et al. Skin explant culture as a model for cutaneous graft-versus-host disease in humans. Bone Marrow Transplant 1988; 3: 323-329.
6. Sviland L, Dickinson AM, Carey PJ et al. An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 105-109.
7. Dickinson AM, Sviland L, Wang XN et al. Predicting graft-versus-host disease in HLA-identical bone marrow transplants - a comparison of T cell frequency analysis and a human skin explant model. Transplantation 1998; 66: 857-863.
8. Hromadníková I, Dickinson AM, Vavrinec J et al. In vitro graft-versus-host disease predictive test for allogeneic haematopoietic stem cell transplantation in children - skin explant model. Clin Oncol 1997; 10: 180-183.
9. Hromadníkovà I, Dickinson AM, Vavrinec J et al. Skin explant model - useful model for studying the pathogenesis of acute GVHD in children. Clin Immunol Allergol 1997; 7: 5-10.
10. Mittal KK, Hickey MR, Singal DP, Terasaki PI. Serotyping for homotransplantation. Refinement of microdroplet lymphocyte cytotoxicity test. Transplantation 1968; 6: 913-927.
11. Olerup O, Zetterquist H. HLA-DR typing by polymerase chain reaction amplification with sequence specific primers (PCR-SSP). In: Hui K, Bidwell J (eds). Handbook of HLA Typing Techniques. CRC Press: Boca Raton, 1993, pp 149-173.
12. Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens 1994; 43: 7-17.
13. Lerner KG, Kao GF, Storb R et al. Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974; 6: 367-371.
14. Vogelsang GB, Hess AD, Berkman AW et al. In vitro predictive test for graft-versus-host disease in patients with genotypic HLA-identical bone marrow transplants. New Engl J Med 1985; 313: 645-650.
15. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation 1974; 18: 295-304.
16. Storb R, Deeg HJ, Farewell V et al. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 1986; 68: 110-125.
17. Storb R, Deeg HJ, Whitehead J et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft-versus-host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
18. Storb R, Deeg HJ, Pepe M et al. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: long-term follow-up of a controlled trial. Blood 1989; 73: 1729-1734.
19. Frassoni F, Labopin M, Gluckman E et al. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - a report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1996; 17: 13-18.
20. Storb R, Leisenring W, Anasetti C et al. Methotrexate and cyclosporine for graft-versus-host disease prevention: what length of therapy with cyclosporine? Biol Blood Marrow Transplant 1997; 3: 194-201.
21. Elmaagacli AH, Beelen DW, Trenn G et al. Introduction of a graft-versus-leukemia reaction by cyclosporin A withdrawal as immunotherapy for leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23: 771-777.
22. Aschan J, Ringden O, Sundberg B et al. Methotrexate combined with cyclosporin A decreases graft-versus-host disease, but increases leukemic relapse compared to monotherapy. Bone Marrow Transplant 1991; 7: 113-119.
23. Ringdén O, Horowitz MM, Sondel P et al. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia? Blood 1993; 81: 1094-1101.
24. Jackson GH, Taylor PRA, Lennard A et al. Single centre experience of allogeneic bone marrow transplantation with GVHD prophylaxis based on cyclosporin alone: March 1983-December 1996. Bone Marrow Transplant 1998; 21 (Suppl. 1): S124.
25. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New Engl J Med 1996; 334: 281-285.
26. Middleton PG, Taylor PRA, Jackson G et al. Cytokine gene polymorphisms associating with severe acute graft-versus-host disease in HLA-identical sibling transplants. Blood 1998; 92: 3943-3948.
27. Dickinson AM. Predicting graft-versus-host disease in bone marrow transplants using in vitro techniques. In: Wakolbinger W, Jarvenpaa M, Le Dour O et al (eds). Examples of Demonstration Projects in the Life Sciences Programmes. (3) Fourth Framework Programme. European Commission: Brussels, 1999 (in press).